 The stock of Halozyme Therapeutics, Inc. has moved up nicely in recent months, buoyed by solid third quarter results and positive commentary from the analyst firm community. However, Halozyme stock is hitting up against some price targets and insiders have notably started to sell off some of their stakes in the firm. 